JP2020517704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517704A5 JP2020517704A5 JP2019558417A JP2019558417A JP2020517704A5 JP 2020517704 A5 JP2020517704 A5 JP 2020517704A5 JP 2019558417 A JP2019558417 A JP 2019558417A JP 2019558417 A JP2019558417 A JP 2019558417A JP 2020517704 A5 JP2020517704 A5 JP 2020517704A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- day
- once daily
- week
- venetoclax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491803P | 2017-04-28 | 2017-04-28 | |
| US62/491,803 | 2017-04-28 | ||
| PCT/US2018/029607 WO2018200841A1 (en) | 2017-04-28 | 2018-04-26 | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115411A Division JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517704A JP2020517704A (ja) | 2020-06-18 |
| JP2020517704A5 true JP2020517704A5 (enExample) | 2022-06-06 |
Family
ID=63919290
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558417A Withdrawn JP2020517704A (ja) | 2017-04-28 | 2018-04-26 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Withdrawn JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
| JP2025202062A Pending JP2026026133A (ja) | 2017-04-28 | 2025-11-21 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Withdrawn JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
| JP2025202062A Pending JP2026026133A (ja) | 2017-04-28 | 2025-11-21 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11364235B2 (enExample) |
| EP (2) | EP4772537A2 (enExample) |
| JP (4) | JP2020517704A (enExample) |
| CN (1) | CN110612109A (enExample) |
| BR (1) | BR112019022308A2 (enExample) |
| CA (1) | CA3059752A1 (enExample) |
| MX (1) | MX2019012660A (enExample) |
| WO (1) | WO2018200841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772537A2 (en) * | 2017-04-28 | 2026-07-08 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
| WO2019094931A1 (en) * | 2017-11-10 | 2019-05-16 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| CA3125197A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| TW202131946A (zh) * | 2020-01-10 | 2021-09-01 | 加拿大商融合製藥公司 | 持續性免疫療法 |
| US20240299600A1 (en) * | 2020-09-08 | 2024-09-12 | Actinium Pharmaceuticals, Inc. | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923985A (en) | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| CA2422291C (en) | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| US8487131B2 (en) * | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| WO2017021963A1 (en) * | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
| EP4772537A2 (en) * | 2017-04-28 | 2026-07-08 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
-
2018
- 2018-04-26 EP EP26175547.4A patent/EP4772537A2/en active Pending
- 2018-04-26 CA CA3059752A patent/CA3059752A1/en active Pending
- 2018-04-26 BR BR112019022308-8A patent/BR112019022308A2/pt unknown
- 2018-04-26 EP EP18792272.9A patent/EP3615047A4/en active Pending
- 2018-04-26 JP JP2019558417A patent/JP2020517704A/ja not_active Withdrawn
- 2018-04-26 US US16/607,168 patent/US11364235B2/en active Active
- 2018-04-26 WO PCT/US2018/029607 patent/WO2018200841A1/en not_active Ceased
- 2018-04-26 CN CN201880027661.XA patent/CN110612109A/zh active Pending
- 2018-04-26 MX MX2019012660A patent/MX2019012660A/es unknown
-
2020
- 2020-07-03 JP JP2020115411A patent/JP2020158544A/ja not_active Withdrawn
-
2022
- 2022-05-16 US US17/745,045 patent/US11844799B2/en active Active
-
2023
- 2023-09-28 JP JP2023168404A patent/JP2023165952A/ja not_active Withdrawn
- 2023-11-02 US US18/500,735 patent/US12133849B2/en active Active
-
2024
- 2024-09-30 US US18/901,169 patent/US20250017919A1/en active Pending
-
2025
- 2025-11-21 JP JP2025202062A patent/JP2026026133A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| King et al. | Use of amifostine for cytoprotection during radiation therapy: a review | |
| JP2020158544A5 (enExample) | ||
| ES2543383T3 (es) | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano | |
| Zadeh et al. | Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1 | |
| Millefiorini et al. | Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome | |
| EP4393490A1 (en) | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma | |
| JP2022525149A5 (enExample) | ||
| JP2022537551A5 (enExample) | ||
| JP2024530189A5 (enExample) | ||
| JP2023502929A5 (enExample) | ||
| JP2022510410A5 (enExample) | ||
| KR20210147083A (ko) | 다발경화증 치료용 조합 요법 | |
| Meijer et al. | Use of sodium thiosulfate as an otoprotectant in patients with cancer treated with platinum compounds: a review of the literature | |
| CA2442168A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| JP2020516646A5 (enExample) | ||
| JP2023508496A5 (enExample) | ||
| JP2022554276A5 (enExample) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
| JPWO2020250915A5 (enExample) | ||
| CN115381939A (zh) | 治疗霍奇金淋巴瘤的药物组合物及其用途 | |
| JP2025511402A5 (enExample) | ||
| Hansen et al. | Phase III study of intermittent 5‐drug regimen (VBCMP) versus intermittent 3‐drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis | |
| JP2022553041A5 (enExample) | ||
| JP2024531799A5 (enExample) |